Expectations trend
FY2028 · fiscal year ending 2028-10-31 · fmp
$5.08 → $5.08 · observed estimates
Cooper Companies (The) (COO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$63.51-1.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for COO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Free cash flow of $600-$625 million in FY 2026 | Free cash flow is strong, guided at $600-$625 million for 2026. | Intact | Free cash flow falls below $500 million in FY 2026 | Free cash flow: $273M FY2026-Q3; GAAP. Published target: >=$600 million. Annual target cannot be compared with a quarterly or TTM observation. Sep 9, 2026273,000,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-10-31 · fmp
$5.08 → $5.08 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 3, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a healthcare business with a long-term thesis tied to profitable growth, cash flow, and operating discipline. The thesis is intact, and recent performance is strong relative to its industry, though management is rated neutral and the evidence confidence is medium.
COO screens cheap versus peers, but the valuation model has low confidence and also indicates a 59% premium versus peers, so the valuation picture is mixed. The expectations gap is negative, meaning expectations appear demanding relative to the evidence; no valuation fragility gates have fired.
Near term, revenue growth is present but momentum was limited in Q3: revenue rose 1% year over year, with channel inventory reductions cited. Operating margin improved year over year through expense control and productivity, although it eased from the prior quarter; share repurchases were substantial. The next guidance update, the CEO transition, and weakening jobs data are risks, while the recent earnings beat and stronger company-momentum reading provide support.
The multi-year view depends on COO sustaining profitable growth and cash flow while improving margins, despite uneven quarterly momentum. Near term, a guidance cut or further labor-market weakening would weigh on the thesis; continued strong results and higher guidance from healthcare peers such as ISRG, BDX, and RMD would support the sector backdrop.
Over the next 1 to 3 years, COO’s thesis remains intact, but its mixed valuation signals, limited recent revenue momentum, and CEO transition leave meaningful execution questions. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Cooper Companies (The)'s published investment case. The stated target is >=21%. |
| Intact |
| Operating margin falls below 19% next year |
Operating margin: 20.82% FY2026-Q3; GAAP. Published target: >=21%. Target period is not explicitly aligned with this observation. Sep 9, 202620.821609 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of about 8% per year | Cooper Companies grows sales about 8% a year. | Intact | YoY revenue growth falls below 5% next year | Revenue growth: 0.56% FY2026-Q3; GAAP. Published target: >=8% YoY. Target period is not explicitly aligned with this observation. Sep 9, 20260.556446 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 5 of 8 supplied quarters. Management reported: “"Following the completion of the strategic review, we are focused on profitable growth, strong cash flow generation, disciplined capital allocation, and maximizing long-term shareholder value."” “"We're pleased to report a strong start to the fiscal year, highlighted by product launches, outstanding profitability, and robust cash flow, all of which gives us the confidence to raise both earnings and free cash flow guidance.” Revenue was $1.066 billion in 2026-Q3. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$4.62B → $4.62B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-11-01 | $5.08 | $4,616,481,053 | 9 / 13 |
| 2026-11-02 | $5.08 | $4,616,481,053 | 9 / 13 |
| 2026-11-03 | $5.08 | $4,616,481,053 | 9 / 13 |
| 2026-11-04 | $5.08 | $4,616,481,053 | 9 / 13 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 11 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.